ATF4 and T-cell acute lymphoblastic leukemia: According to the previous reports, GSK-J4 inhibits lipopolysaccharide-induced TNFα production in human primary macrophages with IC50 of 9 μM21 and blocks growth of T cell acute lymphoblastic leukemia (T-ALL) cells with IC50 of 2 μM (25), indicating that GSK-J4 is a highly potent inducer of ATF4 and CHOP.